Summary & Overview
HCPCS G0533: Weekly Injectable Buprenorphine Medication Assisted Treatment Bundle
HCPCS Level II code G0533 designates a weekly bundled service for medication assisted treatment using injectable buprenorphine, including dispensing/administration, substance use counseling, individual and group therapy, and toxicology testing when performed. It applies when these services are provided by a Medicare-enrolled opioid treatment program. Nationally, this code matters because it standardizes billing for comprehensive weekly MAT services tied to injectable buprenorphine, aligning clinical and administrative reporting for addiction treatment programs and payers.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical scope and service setting, plus payor coverage context. The publication summarizes typical billing practices, common modifiers, and how the bundled weekly structure affects service line reporting and revenue recognition. It also highlights clinical context around injectable buprenorphine delivery and integrated counseling and toxicology services.
This briefing is intended to inform coding professionals, revenue cycle managers, and policy analysts about the national significance of G0533, what services are encompassed by the weekly bundle, and where to focus follow-up for payer-specific coverage rules and documentation requirements. Data not available in the input for payer-specific rates, taxonomies, ICD-10 pairings, and related codes.
Billing Code Overview
HCPCS Level II code G0533 describes a medication assisted treatment (MAT) weekly bundle for injectable buprenorphine. The code represents a weekly package of services that includes dispensing and/or administration of injectable buprenorphine, substance use counseling, individual and group therapy, and toxicology testing if performed. The description specifies that these bundled services are furnished by a Medicare-enrolled opioid treatment program.
Service type: Medication assisted treatment (buprenorphine) bundle, weekly
Typical site of service: Opioid treatment program or outpatient clinic setting where Medicare-enrolled opioid treatment programs operate
Clinical & Coding Specifications
Clinical Context
A 38-year-old adult with moderate to severe opioid use disorder presents to a Medicare-enrolled opioid treatment program (OTP) for weekly maintenance treatment with injectable buprenorphine. The patient checks in at the clinic intake desk for medication administration, receives a brief nursing assessment (vitals, brief withdrawal screen), and is administered a weekly subcutaneous or intramuscular buprenorphine injection by a licensed clinician. The bundled service includes dispensing/administration of the medication, one-on-one substance use counseling, enrollment in weekly individual or group therapy sessions, and collection of urine toxicology specimens when indicated. Clinical documentation includes diagnosis of opioid use disorder, informed consent for medication-assisted treatment, medication administration record, counseling notes, therapy attendance records, and toxicology results. The workflow typically involves scheduling the weekly visit, verification of provider enrollment and patient eligibility, medication preparation and controlled substance handling per state and federal rules, administration and observation for immediate adverse effects, and delivery of psychosocial services during the same encounter. Billing uses G0533 for the weekly bundled service provided by the Medicare-enrolled OTP.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no other modifier applies |